XGenomes
PrivateLast Round
Grant
Jul 15, 2024
Est. Valuation
$2.14M
Total Funding Raised
$22.79M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
XGenomes operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Grant round in July 2024.
XGenomes is a biotechnology company developing a next-generation DNA sequencing platform that utilizes novel biochemistry, super-resolution single-molecule imaging, and artificial intelligence to provide rapid, accurate, and cost-effective genomic data.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Hardware + Subscription, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
XGenomes Comparables
Compare XGenomes with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Oxford Nanopore Technologies plc | 73% | |
| Illumina, Inc. | 71% | |
| Ultima Genomics | 70% |
For institutional investors. Book with your work email.
XGenomes Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jul 15, 2024 | ||||
| Series A | Oct 26, 2021 | ||||
| Seed | Sep 4, 2019 | ||||
| Grant | Sep 3, 2019 | ||||
| Accelerator | Mar 18, 2019 | ||||
Grant | Jan 1, 2018 |
For institutional investors. Book with your work email.
XGenomes Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Better Ventures | Seed |
| RA Capital Management | Series A |
| The Engine | Series A |
| Engine Ventures | Seed |
| U.S. Department of Health and Human Services | Grant |
| B Capital Group | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 10, 2026
Open roles increased to 10, 125% of headcount.
- Aug 3, 2026
Open roles increased to 6, 3x the trailing average.
For institutional investors. Book with your work email.
XGenomes Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about XGenomes's valuation, stock price, and market status.
Is XGenomes a public or private company?
XGenomes is a private company.
What is the current stock price of XGenomes?
XGenomes is a private company, so its shares have no public market price. Caplight tracks XGenomes's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is XGenomes worth (valuation)?
XGenomes's valuation is estimated at $2.1M based on funding round data.
Can I buy XGenomes stock?
XGenomes shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was XGenomes's last funding round?
XGenomes's most recent funding round was Grant on July 15, 2024.
Who are the main investors in XGenomes?
Key investors in XGenomes include National Cancer Institute, RA Capital Management, NIH RADx, Northpond Ventures, Massachusetts Life Sciences Center.
Will XGenomes IPO soon?
No public IPO plans have been announced for XGenomes.
How can I track XGenomes secondary market activity?
Caplight tracks bids, offers, and trades in XGenomes's shares on secondary markets.